Testing two biologic asthma medicines to see how patients respond

Trial details

Who runs it

University of California, San Diego

Trial code

NCT06385236

Record updated

19 August 2024

Original description

In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples.Read full original descriptionShow less

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

In this study, a new method will be used to evaluate response to 2 approved biologic therapies, and assess how well each patient responds to each asthma treatment. This study will measure the response to these treatments using genomic and biologic measurements obtained from participants biosamples.

By evaluating response to 2 different biologic therapies, this study has the potential to provide an in-depth understanding of the mechanisms underlying severe asthma that will inform and change treatment decisions, and may ultimately lead to a change in the way that asthma patients are evaluated for potential personalized therapies and maximize the probability that the subject will respond to treatment.

Inclusion: Stated willingness to comply with all study procedures and availability for the duration of the study; Stable asthma medications: No change in asthma medications for the past 2 months:; Use of medium or high dose inhaled corticosteroids (ICS) AND; Use of an additional asthma controller medication; Baseline poor or uncontrolled asthma; Evidence of asthma demonstrated by either bronchodilator reversibility (either at screening or by historical evidence) or methacholine responsiveness (by historical evidence); Agreement to adhere to Lifestyle Considerations throughout study duration.

Exclusion: Current participation in an interventional trial (e.g. drugs, diets, etc.); Currently on an asthma biologic or having been on biologic within 3 months of screening; Enrollment in a clinical trial where the study medication was administered within the past 60 days or within 5 half-lives (whichever is greater); Receiving one or more immune-modulating therapies for diseases other than asthma. This includes biologics that are also approved for asthma; Receiving methotrexate, mycophenolate (CellCept®), or azathioprine (Imuran®); Receiving aero allergen immunotherapy and not on at least 3 months of maintenance allergen immunotherapy; Requirement for daily systemic corticosteroids at the time of screening; Physician diagnosis of other chronic pulmonary disorders associated with asthma-like symptoms, including, but not limited to, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, severe scoliosis or chest wall deformities that affect lung function, or congenital disorders of the lungs or airways; Uncontrolled hypertension, defined as systolic blood pressure > 160 mm/Hg or diastolic blood pressure > 100 mm/Hg; History of malignancy except non-melanoma skin cancer within the last five years; Respiratory infection within 1 month of screening; Allergic to any of the drugs, biologics or chemicals used in this study; History of smoking:; If <45 years old: Smoked for ≥5 pack-years*; If ≥45 years old: Smoked ≥ 10 pack years; Underwent a bronchial thermoplasty within the last two years; Born before 30 weeks of gestation; Active use of any inhalant >1 time per month in the past year; Substance abuse within the last year; Unwillingness to practice medically acceptable birth control or complete abstinence during the study, current pregnancy, or lactation; Intubation for asthma in the last 12 months; Any clinically significant abnormal findings in the history, physical examination, vital signs, electrocardiogram, hematology or clinical chemistry during run-in period, which in the opinion of the site investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study; BMI > 38.

ClinicalTrials.gov NCT06385236